Adverum Biotechnologies, Inc. financial data

Symbol
ADVM on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
100 Cardinal Way, Redwood City, CA
Fiscal year end
December 31
Former names
Avalanche Biotechnologies, Inc. (to 5/10/2016)
Latest financial report
10-K - Q4 2024 - Apr 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 843 % +93.3%
Debt-to-equity 81.3 % -15.3%
Return On Equity -109 % +7.42%
Return On Assets -60.2 % -0.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 20.9M shares -89.9%
Common Stock, Shares, Outstanding 20.8M shares +106%
Entity Public Float 137M USD -9.95%
Common Stock, Value, Issued 2K USD +100%
Weighted Average Number of Shares Outstanding, Basic 19.8M shares +96.2%
Weighted Average Number of Shares Outstanding, Diluted 19.8M shares +96.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1M USD -72.2%
Research and Development Expense 77M USD -0.57%
General and Administrative Expense 63.1M USD +14.6%
Operating Income (Loss) -139M USD -7.92%
Nonoperating Income (Expense) 7.86M USD +38.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -131M USD -6.28%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -131M USD -7.22%
Earnings Per Share, Basic -6.62 USD/shares +45.3%
Earnings Per Share, Diluted -6.62 USD/shares +45.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 60.7M USD -19.1%
Cash, Cash Equivalents, and Short-term Investments 126M USD +30.3%
Assets, Current 131M USD +27.8%
Property, Plant and Equipment, Net 11.6M USD -21.4%
Operating Lease, Right-of-Use Asset 33.6M USD -4.03%
Other Assets, Noncurrent 1.35M USD +9.42%
Assets 180M USD +15.5%
Accounts Payable, Current 1.61M USD -16.2%
Liabilities, Current 22.9M USD +14.6%
Operating Lease, Liability, Noncurrent 86M USD +25.5%
Other Liabilities, Noncurrent 192K USD
Liabilities 109M USD +23.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -407K USD +14%
Retained Earnings (Accumulated Deficit) -1.07B USD -14%
Stockholders' Equity Attributable to Parent 70.7M USD +5.2%
Liabilities and Equity 180M USD +15.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.2M USD -3.72%
Net Cash Provided by (Used in) Financing Activities 120M USD
Net Cash Provided by (Used in) Investing Activities -22M USD -202%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 20.8M shares +106%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 74.6M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 62.6M USD -18.6%
Deferred Tax Assets, Valuation Allowance 232M USD +12.7%
Deferred Tax Assets, Gross 240M USD +11.5%
Operating Lease, Liability 91.7M USD +22.2%
Payments to Acquire Property, Plant, and Equipment 90K USD +5.88%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -131M USD -8.1%
Lessee, Operating Lease, Liability, to be Paid 167M USD +18.4%
Property, Plant and Equipment, Gross 29.7M USD +1.28%
Operating Lease, Liability, Current 5.67M USD +3.51%
Lessee, Operating Lease, Liability, to be Paid, Year Two 14.9M USD +30.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.1M USD +9.53%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 75.5M USD +14%
Lessee, Operating Lease, Liability, to be Paid, Year Three 15.3M USD +29.2%
Deferred Tax Assets, Operating Loss Carryforwards 137M USD +7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 27.2M USD +19.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 15.7M USD +28.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 7.99M USD -15.5%
Share-based Payment Arrangement, Expense 14.4M USD -18.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%